A Phase 2 interventional study of Niclosamide and Placebo in Covid19, sponsored by UNION therapeutics. Terminated at 3 sites in Germany. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-02-21.
Sponsored by UNION therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 226 studies in COVID-19 with a site in Germany — 21 open to participants now, 27 under way, 7 of them phase 3. COVID-19 · Germany.
Among the 226 studies in COVID-19 with a site in Germany, this one is the 122nd largest by enrollment of the 130 interventional ones that give a count, is one of 60 that started in 2021, is one of 28 in phase 2, and was the 153rd registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →21 of the 226 studies in COVID-19 with a site in Germany are open now. Recruiting first, the newest first:
Charite University, Berlin, Germany · Sites in Germany
Ages 18+
Pfizer · Sites in Germany, United States, Argentina and 15 more countries
Ages 18+
Pfizer · Sites in Germany, United States, Argentina and 16 more countries
Ages 12+
Merck Sharp & Dohme LLC · Sites in Germany, United States, Argentina and 21 more countries
Ages 18+
Technical University of Munich · Sites in Germany, Austria, Belgium and 2 more countries
Ages 3 mo–4 mo · Healthy volunteers
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 45 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
226 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 48 · Phase 3 46 · Phase 4 5
First in 2016; this study’s year is marked. 60 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4 is below the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 135 across the 130 interventional studies, 410 across the 94 observational. Of the 153 that completed or were terminated, 48 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
69 of 226 have an industry lead sponsor. The 10 most frequent:
UNION therapeutics is the lead sponsor of 10 studies on the registry; none are open to participants now.
UNION therapeutics has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
9 of the studies in COVID-19 with a site in Germany that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03188796Phase 3Medical University of GrazThe VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients | 2027-07 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05389319University Hospital TuebingenA Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 226 studies in COVID-19 with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and efficacy of UNI91103 intranasal spray for treatment of coronavirus disease 2019 (COVID-19) in asymptomatic or mildly symptomatic adults.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
None of the symptoms should have been present >5 days.
Exclusion Criteria:
UNI91103 intranasal spray 1%, BID, 10 consecutive days
Drug: Niclosamide
Placebo intranasal spray, BID, 10 consecutive days
Drug: Placebo
Niclosamide is a broad spectrum, host targeting antiviral that inhibits viral replication (by neutralizing endosomal pH) and increases viral clearance (by increasing the autophagic flux). The niclosamide solution is administered directly to the nasal cavity via a nasal spray.
The placebo formulation contains purified water, sodium chloride as common isotonizing agent and the FAO/WHO approved colorant FD\&C Red 40 to match the red-orange colour of the active solution. The solution is administered directly to the nasal cavity via a nasal spray.
Proportion of subjects with worsened symptoms any time from Day 3 to Day 10 compared with baseline
Worsening is assessed by the Food and Drug Administration (FDA) COVID-19 Symptom Questionnaire, assessing severity of symptoms over the past 24 hour period.
Time frame: Day 3 to Day 10
Proportion of subjects with worst intensity/grade up to Day 10 and up to Day 15 in any single symptoms in the 3 domains of the FDA COVID-19 questionnaire
Assessed by the FDA COVID-19 symptom questionnaire divided into 3 domains - Items 1 to 10, items 11 to 12 and items 13 to 14
Time frame: Day 10 and up to Day 15
Proportion of subjects reporting the following number of symptoms with worst intensity/severe grade: ≥ 1 symptom, ≥ 2 symptoms, ≥ 3 symptoms, etc.
Assessed by the FDA COVID-19 symptom questionnaire looking at the individual symptoms
Time frame: Any time point
Proportion of subjects with worsened symptoms at Day 15 compared with baseline.
Worsening is assessed by the FDA COVID-19 Symptom Questionnaire, which is a self reported questionnaire assessing severity of symptoms over the past 24 hour period.
Time frame: Day 15
Change from baseline in each single symptom score
Assessed by the FDA COVID-19 symptom questionnaire looking at the individual symptoms
Time frame: Days 10, 15 and 30
Proportion of subjects who are asymptomatic on Day 10
Assessed by the FDA COVID-19 symptom questionnaire
Time frame: Day 10
Proportion of subjects requiring visits to urgent care (UC) or emergency department (ED) facilities, or hospitalization because of signs or symptoms of COVID-19
Number of visits to urgent care (UC) or emergency department (ED) facilities, or hospitalization is assessed by a self developed questionnaire
Time frame: Day 10, 15 and 30
Proportion of subjects admitted to intensive care units (ICU) and/or died
Assessed by WHO 11-point Ordinal Scale
Time frame: At screening, Day 1, and every other day through Day 10, and again at Day 15 and Day 30
Change from baseline in SARS-CoV-2 viral load at Day 5 and Day 10
Assessed by quantitative reverse transcription polymerase chain reaction (qRT-PCR)
Time frame: Day 5 and Day 10
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2021 to primary completion in Jan 2022, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Niclosamide
UNION therapeutics